Two more firms that advise shareholders on proxy voting—Glass, Lewis & Co. and Proxy Governance—have recommended shareholders of Amylin Pharmaceuticals (NASDAQ: [[ticker:AMLN]]) throw their support behind dissident directors nominated by Eastbourne Capital and billionaire investor Carl Icahn. Glass Lewis is recommending shareholders vote for three of the five dissidents nominated to the 12-member board, while Proxy Governance is recommending all five dissidents. On Friday, another leading proxy adviser, RiskMetrics Group, recommended dissidents win three seats on the board.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
